The Future of Plaque Psoriasis Treatment
Brad Glick, DO, MPH; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, comment on the future of plaque psoriasis treatment and share clinical pearls on the management of plaque psoriasis.
Read More
The Impact of Non-Steroidal Topical Agents in Plaque Psoriasis
Expert dermatologists comment on the use of nonsteroidal topical therapies in the treatment of plaque psoriasis and how it has affected clinical practice.
Clinical Trials of Roflumilast in Plaque Psoriasis
Experts discuss the DERMIS clinical trials of roflumilast in the treatment of plaque psoriasis, highlighting its efficacy in the intertriginous areas.
Long-Term Study Data of Tapinarof in Plaque Psoriasis
Mona Shahriari, MD, and Linda Stein Gold, MD, review the long-term safety and efficacy data of tapinarof as well as its use in clinical practice for the management of plaque psoriasis.
Emerging Treatment in Plaque Psoriasis
Experts in dermatology discuss recent advances in the plaque psoriasis treatment toolbox, highlighting the mechanism of action and data of tapinarof.
Use of Topical Therapy in Mild-to-Moderate Plaque Psoriasis
Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.
Remittive and Suppressive Therapy in Plaque Psoriasis
Experts share the difference between the remittive and the suppressive effect in plaque psoriasis and how to get patients there.
Managing Plaque Psoriasis in Difficult-to-Treat Areas
Expert dermatologists discuss plaque psoriasis in difficult-to-treat areas such as skin folds and the face, highlighting which types of treatments they recommend.
Treatment Selection for Patients With Plaque Psoriasis
Linda Stein Gold, MD; Mona Shahriari, MD; and Michael Cameron, MD, FAAD, share approaches to choosing between systemic and topical therapies or combination therapies to treat plaque psoriasis.
Standard of Care for Patients With Plaque Psoriasis
Experts discuss the current standard of care for patients with moderate-to-severe plaque psoriasis, focusing on whether the patient is a candidate for systemic or topical treatment.
Current Treatment Options in Plaque Psoriasis
Expert dermatologists provide an overview of the current topical, oral, and biologic medications available to treat plaque psoriasis.
Disease Burden of Plaque Psoriasis
Linda Stein Gold, MD, and Mona Shahriari, MD, comment on the psychological impact plaque psoriasis has on patients, garnering an increased risk of anxiety and depression.
Demographics and Pathogenesis of Plaque Psoriasis
Brad Glick, MD; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, provide an overview of plaque psoriasis, highlighting demographics and risk factors, as well as the pathophysiology of the disease.
Pearls for Atopic Dermatitis Management
Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.
Patient Adherence in Atopic Dermatitis
Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.
Use of Tralokinumab in Atopic Dermatitis
Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.
Impact of Dupilumab on Quality of Life for Atopic Dermatitis Patients
Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.
Efficacy and Reported Outcomes With JAK Inhibitors in Atopic Dermatitis
Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.
Ideal Candidates for Ruxolitinib Treatment of Atopic Dermatitis
Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.
Safety Profile of Topical Ruxolitinib in Atopic Dermatitis
Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.
Future Directions in the Use of TYK2 Inhibitors for the Treatment of Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, review the clinical and practical impact of TYK2 inhibition and its evolving role within the treatment landscape for psoriatic disease.
Potential Uses for TYK2 Inhibitor Regiments in Plaque Psoriasis and Psoriatic Arthritis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the potential use of TYK2 inhibitors in combination with other modalities.
Navigating Treatment Access Challenges in Patients With Plaque Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, share considerations for ensuring that patients on Medicare and Medicaid receive the appropriate medication.
Clinical Trials of Topical Ruxolitinib in Atopic Dermatitis
Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.
Overview of JAK Inhibitors in Atopic Dermatitis
Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.
Expert Insights on Therapeutic Selection for the Treatment of Plaque Psoriasis
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, discuss the nuances of treatment selection for patients with moderate to severe plaque psoriasis.
Laboratory Evaluations for TYK2 Inhibitors in the Treatment of Psoriasis
Thought leaders talk about blood monitoring protocols with deucravacitinib.
Assessing Severity of Atopic Dermatitis
Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.
Treatment Approach to Atopic Dermatitis
Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.
Reviewing the Safety Profile of Deucravacitnib
Linda Stein Gold, MD, and Bruce Strober, MD, PhD, place the safety data for deucravacitinib in clinical context.